Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

Summary

Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia

Timeline

Start

2023-03-06

Primary completion

2023-12-14

Completion

2024-01-24

Outcome

Met primary endpoint

registry analysis (superiority test); Aceclidine + Brimonidine (LNZ101); p <0.0001; Odds Ratio (OR) 20.69; Generalized Estimating Equation (GEE) NCT05728944 ↗

registry analysis (superiority test); Aceclidine Ophthalmic Solution (LNZ100); p <0.0001; Odds Ratio (OR) 38.85; Generalized Estimating Equation (GEE) NCT05728944 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aceclidine	Small molecule	—	—
Subject	Brimonidine	Unknown	—	—

Indications